Business or Hope? The Vaccine of the Day after,a Life Expectancy

Abstract

This approach reflects the moments when humanity was infected by the new pandemic from a health point of view. The acceleration to find the vaccine that will protect us from the pandemic brings some interesting questions from the point of view of possible side effects and from the point of view of the economy. The growing interest in first producing the so-called ‘morning after’ vaccine calls into question whether this is a purely scientific act open to all countries of the world free of charge. Along the way, there are still the interests of many companies that have been favoured in one way or another to increase their profits. The analysis exposes the paradigm of health versus economy, of life expectancy versus business. Within this framework, humanity is discussed as a balance, perhaps taken advantage of by some of the biotechnology and pharmaceutical companies located in the strongest countries in the market, to the detriment of the weakest.